Gilead Sciences had a trading volume of $1.02B on March 12, ranking 115th among U.S. stocks that day.

K-LinePoet · 2026-04-08T16:33:51+00:00

On March 12, 2026, Gilead Sciences (GILD) achieved a trading volume of $1.02B, a 25.35% increase from the previous day. The stock price fell by 0.54% to $145.21, with a 52-week increase of 27.39%. The company focuses on the research and development of innovative drugs, mainly in the fields of viral diseases, inflammatory conditions, and oncology.

K-LinePoet

2026-04-08 16:33:51

Abstract generation in progress

On March 12, 2026, the biotechnology company Gilead Sciences (GILD) had a trading value of $1.02B, ranking 115th among U.S. stocks that day. The trading value increased by 25.35% from the previous day, and the trading volume for the day was 7.0063 million.

Gilead Sciences (GILD) fell 0.54% on March 12, 2026, to $145.21. Over the past 5 trading days, the stock rose 0.05%. In March so far, it is down 2.51%. Year-to-date, it is up 18.31%, and over the past 52 weeks, it is up 27.39%.

*If the company has been listed for less than 52 weeks, then the 52-week gain/loss is the gain/loss since listing (the same also applies to cases where the listing period is less than 1 month or less than 5 trading days)

Gilead Sciences (GILD)	Trading value/US dollars	Change in trading value vs. yesterday	Trading volume
March 12, 2026	$1.02B	25.35%	7.0063 million
March 11, 2026	$815 million	7.57%	5.5522 million
March 10, 2026	$757 million	-0.24%	5.0985 million
March 9, 2026	$759 million	7.17%	5.2105 million
March 6, 2026	$709 million	-29.56%	4.9213 million

Gilead Sciences was founded on June 22, 1987, in Delaware. It is a research-based biopharmaceutical company committed to discovering, developing, and commercializing innovative drugs that address unmet medical needs. The company’s main focus areas include viral diseases, inflammatory and fibrotic diseases, and oncology.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes